A project newsletter has just been published which gives an overview of the progress of BIO-NMD – an EU funded project searching for biomarkers in patients with Duchenne and Becker muscular dystrophies and collagen 6-related myopathies (which includes Ullrich congential muscular dystrophy and Bethlem myopathy).
Biomarkers are substances in the body that offer a way to measure normal or abnormal processes. This means that processes associated with particular diseases can be measured and disease progression monitored. A biomarker may be a protein found in bodily fluids such as the blood or urine, or in tissues such as the muscles. Alternatively, the activity of a particular gene could be a biomarker.
Biomarkers may allow clinical trials to take place more quickly and cheaply and provide a more sensitive way to measure effects of the treatment. They may also reduce the use of muscle biopsies, aid an earlier diagnosis, measure disease progression more accurately and allow treatments to be ‘personalised’ to more precisely meet the needs of individual patients.
The three-year BIO-NMD project is now in its final year. A project newsletter has just been published which provides an overview of the progress and activity within BIO-NMD as well as some related news items from patient organisations. This newsletter can be viewed here.
Further information and links
More information about BIO-NMD.
It is only through your contributions that we can continue to fund the vital work that takes us closer to finding treatments and cures for muscle disease. Donate now and help change the lives of thousands of people living with muscle disease.